TWiV 1062: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Coverage with selected vaccines and exemption from school vaccine requirements among (CDC)
- Seasonality of endemic COVID-19 (Virology)
- mRNA SARS-CoV-2 vaccination before vs during pregnancy and Omicron infection among infants (JAMA)
- Extracting symptoms from responses using ChatGPT among COVID-19 cases (CMI)
- SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
- Optimization of antiviral therapy in immunocompromised COVID-19 patients (ClinicalTrials)
- A study to learn about nirmatrelvir/ritonavir in people with COVID-19 and a compromised immune system (ClinicalTrials)
- Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection (EJP)
- Effect of neutralizing monoclonal antibody treatment on virologic and immunologic biomarkers in patients with COVID-19 (JID)
- SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV on TWiV 1062
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Coverage with selected vaccines and exemption from school vaccine requirements among (CDC)
- Seasonality of endemic COVID-19 (Virology)
- mRNA SARS-CoV-2 vaccination before vs during pregnancy and Omicron infection among infants (JAMA)
- Extracting symptoms from responses using ChatGPT among COVID-19 cases (CMI)
- SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
- Optimization of antiviral therapy in immunocompromised COVID-19 patients (ClinicalTrials)
- A study to learn about nirmatrelvir/ritonavir in people with COVID-19 and a compromised immune system (ClinicalTrials)
- Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection (EJP)
- Effect of neutralizing monoclonal antibody treatment on virologic and immunologic biomarkers in patients with COVID-19 (JID)
- SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV on TWiV 1062
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.